These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18041816)

  • 1. Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.
    Peters EC; Gray NS
    ACS Chem Biol; 2007 Oct; 2(10):661-4. PubMed ID: 18041816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
    Gyenis L; Turowec JP; Bretner M; Litchfield DW
    Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
    Bantscheff M; Eberhard D; Abraham Y; Bastuck S; Boesche M; Hobson S; Mathieson T; Perrin J; Raida M; Rau C; Reader V; Sweetman G; Bauer A; Bouwmeester T; Hopf C; Kruse U; Neubauer G; Ramsden N; Rick J; Kuster B; Drewes G
    Nat Biotechnol; 2007 Sep; 25(9):1035-44. PubMed ID: 17721511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative proteomics of kinase inhibitor targets and mechanisms.
    Daub H
    ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.
    Dar AC; Shokat KM
    Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome-wide discovery of unknown ATP-binding proteins and kinase inhibitor target proteins using an ATP probe.
    Adachi J; Kishida M; Watanabe S; Hashimoto Y; Fukamizu K; Tomonaga T
    J Proteome Res; 2014 Dec; 13(12):5461-70. PubMed ID: 25230287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of kinase-selective inhibitors by chemical proteomics.
    Daub H
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):183-90. PubMed ID: 16198161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors.
    Olaharski AJ; Bitter H; Gonzaludo N; Kondru R; Goldstein DM; Zabka TS; Lin H; Singer T; Kolaja K
    Toxicol Sci; 2010 Nov; 118(1):266-75. PubMed ID: 20810542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity.
    Krishnamurty R; Maly DJ
    Comb Chem High Throughput Screen; 2007 Sep; 10(8):652-66. PubMed ID: 18045078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of kinase inhibitor selectivity by chemical proteomics.
    Daub H; Godl K; Brehmer D; Klebl B; Müller G
    Assay Drug Dev Technol; 2004 Apr; 2(2):215-24. PubMed ID: 15165517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalent inhibitors of protein kinases.
    Gower CM; Chang ME; Maly DJ
    Crit Rev Biochem Mol Biol; 2014; 49(2):102-15. PubMed ID: 24564382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
    Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
    Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
    Duncan JS; Haystead TA; Litchfield DW
    Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design, annotation, and application of a kinase-targeted library.
    Xi H; Lunney EA
    Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
    Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
    J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A structural atlas of kinases inhibited by clinically approved drugs.
    Wang Q; Zorn JA; Kuriyan J
    Methods Enzymol; 2014; 548():23-67. PubMed ID: 25399641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
    Chuaqui C; Deng Z; Singh J
    J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The logic and design of analog-sensitive kinases and their small molecule inhibitors.
    Lopez MS; Kliegman JI; Shokat KM
    Methods Enzymol; 2014; 548():189-213. PubMed ID: 25399647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.